183 related articles for article (PubMed ID: 20457723)
1. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
Yoo C; Kim JE; Lee JL; Ahn JH; Lee DH; Lee JS; Na S; Kim CS; Hong JH; Hong B; Song C; Ahn H
Jpn J Clin Oncol; 2010 Oct; 40(10):980-5. PubMed ID: 20457723
[TBL] [Abstract][Full Text] [Related]
2. Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.
Miyake H; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2018 Jun; 38(6):3593-3599. PubMed ID: 29848715
[TBL] [Abstract][Full Text] [Related]
3. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
Akaza H; Naito S; Ueno N; Aoki K; Houzawa H; Pitman Lowenthal S; Lee SY
Jpn J Clin Oncol; 2015 Jun; 45(6):576-83. PubMed ID: 25917359
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
Kim HS; Hong MH; Kim K; Shin SJ; Ahn JB; Jeung HC; Chung HC; Koh Y; Lee SH; Bang YJ; Rha SY
Oncology; 2011; 80(5-6):395-405. PubMed ID: 21829041
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
Lee SH; Bang YJ; Mainwaring P; Ng C; Chang JW; Kwong P; Li RK; Sriuranpong V; Toh CK; Yuan J; Pitman Lowenthal S; Chung HC
Asia Pac J Clin Oncol; 2014 Sep; 10(3):237-45. PubMed ID: 24576311
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt.
Edesa WA; Abdelmalek RR
Asian Pac J Cancer Prev; 2015; 16(5):1971-6. PubMed ID: 25773796
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
11. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
Tomita Y; Shinohara N; Yuasa T; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Uemura H; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Dec; 40(12):1166-72. PubMed ID: 20713418
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
van der Veldt AA; Boven E; Helgason HH; van Wouwe M; Berkhof J; de Gast G; Mallo H; Tillier CN; van den Eertwegh AJ; Haanen JB
Br J Cancer; 2008 Jul; 99(2):259-65. PubMed ID: 18594533
[TBL] [Abstract][Full Text] [Related]
13. Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.
Liu X; Fiocco M; Swen JJ; Guchelaar HJ
Acta Oncol; 2017 Apr; 56(4):582-589. PubMed ID: 27924664
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
Fujita T; Iwamura M; Ishii D; Tabata K; Matsumoto K; Yoshida K; Baba S
Int J Urol; 2012 Oct; 19(10):908-13. PubMed ID: 22671963
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma.
Shi HZ; Tian J; Li CL
Asia Pac J Clin Oncol; 2015 Dec; 11(4):328-33. PubMed ID: 26471774
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S; Iacovelli R; Boni L; Rizzo M; Derosa L; Rossi M; Galli L; Procopio G; Sisani M; Longo F; Santoni M; Morelli F; Di Lorenzo G; Altavilla A; Porta C; Camerini A; Escudier B;
Ann Oncol; 2015 Oct; 26(10):2107-13. PubMed ID: 26216384
[TBL] [Abstract][Full Text] [Related]
20. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
